Oversight and Government Reform
Since coming to Congress in 1992, Carolyn Maloney has served on the House Committee on Oversight and Government Reform, the main investigative committee in the U.S. House of Representatives. This committee has jurisdiction to investigate any federal program and any matter with federal policy implications. Congresswoman Maloney also sits on the Government Operations subcommittee and previously served on the National Security Subcommittee and as the ranking member of the Subcommittee on the Census.
Congresswoman Carolyn Maloney supports strong oversight and management of federal programs and taxpayer dollars. She has continuously fought to curtail gun trafficking, support the mission of the Census Bureau, reform the system that allowed private companies to underpay for oil extracted on federal lands, prevent further erosion of reproductive choice for women in America, and ensure the postal service remains solvent and continues its presence in our communities.
01/26/15 - H.R.532, Federal Employees Paid Parental Leave Act [114th Congress]
01/14/15 - H.Res. 32, Expressing the sense of the House of representatives that the Citizens' Stamp Advisory Committee, as an entitiy of the United States Postal Service, should issue a commerative Stamp in honor of the holiday of Diwali. [114th Congress]
06/06/13 - H.R.2291, To designate the facility of the United States Postal Service located at 450 Lexington Avenue in New York, New York, as the "Vincent R. Sombrotto Post Office" [Signed into law 08/08/14. 113th Congress]
05/9/13 - H.R.1942, Construction Quality Assurance Act [113th Congress]
02/5/13 - H.R.517, Federal Employees Paid Parental Leave Act [113th Congress]
01/25/13 - H.Res. 47, Expressing the sense of the House of representatives that the Citizens' Stamp Advisory Committee, as an entitiy of the United States Postal Service, should issue a commerative Stamp in honor of the holiday of Diwali. [113th Congress]
More on Oversight and Government Reform
WASHINGTON, DC - This week, Congresswoman Carolyn B. Maloney (D-NY), Chairwoman of the Committee on Oversight and Reform, and Congressman Jimmy Gomez (CA-34) reintroduced the Executive Branch Conflict of Interest Act. This legislation, championed by the late Chairman Elijah E. Cummings, reduces the influence of industry lobbyists on senior government officials and addresses the revolving door between lobbying firms and the government by strengthening and enhancing ethics requirements for federal employees.
The federal government has finally released an obscure 232-page government document central to the Biden administration's efforts to get its team in place by Inauguration Day.
The Plum Book, as it's unofficially called, contains details about the roughly 9,000 coveted leadership jobs in the federal government.
It normally arrives by early December of a presidential election year, just in time for the incoming White House team.
A new pilot study funded by the Food and Drug Administration could be the first step toward lifting restrictions on blood donations by gay and bisexual men.
The program, called Assessing Donor Variability and New Concepts in Eligibility (Advance), has been launched by three of the nation’s largest blood centers — the American Red Cross, Vitalant and OneBlood.
Two members of the Sackler family who served on the board of Purdue Pharma in 2018 testified before the U.S. House under threat of subpoena Thursday, where they answered questions about their role in the opioid epidemic.
Lawmakers on the Committee on Oversight and Reform peppered David and Dr. Kathe Sackler with questions in the at-times testy hearing.
Corporate leaders from OxyContin-maker Purdue Pharma expressed contrition on Thursday for their company’s role in fueling the opioid crisis amid a torrent of criticism from lawmakers of both parties over the drug manufacturer’s conduct.
“I still feel absolutely terrible that a product created to help, and has helped so many people, has also been associated with death and addiction,” David Sackler, a member of the family that owns Purdue and a member of the company’s board from 2012 to 2018, told the House Oversight Committee at a hearing on Thursday.
Two members of the wealthy Sackler family who own OxyContin maker Purdue Pharma LP offered apologies on Thursday for the role the prescription painkiller has played in the deadly U.S. opioid epidemic but sought to deflect personal responsibility in response to withering criticism from lawmakers.
Two members of the Sackler family, heirs to the Purdue Pharma fortune built off the profits of the blockbuster pain drug OxyContin, expressed regret during a Congressional hearing on Thursday, though they did not admit wrongdoing. But members of the House Oversight Committee said the apology was too little, too late, as more than 750,000 Americans have died from drug overdoses in the last two decades, with opioids responsible for 70% of overdose deaths in 2018.
Members of the Sackler family and Purdue Pharma's CEO say they did nothing wrong during the years their company illegally marketed Oxycontin and other opioids.
"There's nothing I can find that I would have done differently," said Dr. Kathe Sackler who served on Purdue's board for nearly 20 years.
Two key House panels on Thursday announced a joint investigation into the massive cyberattack that has impacted multiple federal agencies, in what may be one of the most damaging digital intrusions in years.
In a surprise development, two members of the Sackler family who served on Purdue Pharma's board until 2018 are testifying Thursday morning under oath before the House Committee on Oversight and Reform.
Their privately owned company developed and aggressively marketed Oxycontin in the 1990s, growing into one of the nation's most profitable opioid producers.
David Sackler, Dr. Kathe Sackler and three other family members face a wave of civil lawsuits tied to their alleged role fueling the nation's addiction crisis.